Review Goals Overview

This FDA-TRACK report summarizes the review goals for the Prescription Drug User Fee Act (PDUFA). PDUFA is a law that governs the fees paid by pharmaceutical companies to the FDA, and it plays a key role in improving the efficiency of the new drug approval process. This review aims to evaluate the achievement of existing goals and assess the need for future adjustments.

Policy Background

PDUFA was introduced in 1992 to strengthen the FDA's budget and improve the speed of new drug reviews. Recent increases in healthcare costs and the expansion of new drug pipelines have triggered a policy review, which is a strategic move by regulatory authorities to allocate resources efficiently. Therefore, this review can be seen as an attempt to rebalance cost recovery and review quality.

Market Impact

Pharmaceutical companies maintain a cooperative relationship with the FDA through PDUFA fees, and their new drug launch schedules are affected. If the review goals are strengthened, there is a possibility of increased fees, which could be an important variable in corporate cash flow management. Conversely, if the goals are relaxed, the cost burden may be reduced, which could expand the scope for research and development investment.

Future Outlook

The FDA will renegotiate the next PDUFA agreement based on the review results, which are likely to be implemented from 2025. The industry needs to review its financial strategies and strengthen its regulatory response system in preparation for policy changes. Ultimately, the goal is to find the optimal balance between the speed of new drug approvals and the assurance of safety.